Novel catecholamine prodrugs for use in the treatment of Parkinson's disease

JP2023552699A5Active Publication Date: 2024-11-12H LUNDBECK AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528989
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-17
Filing Date
2021-11-15
Publication Date
2024-11-12
Estimated Expiration
2041-11-15

AI Technical Summary

Technical Problem

Current treatments for Parkinson's disease, such as L-DOPA and apomorphine, face complications like dyskinesia and poor pharmacokinetic profiles, and existing catecholamine prodrugs have issues with oral bioavailability and unpredictable conversion to active compounds.

Method used

Development of novel sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, which are designed to improve oral bioavailability and pharmacokinetic profiles, allowing for sustained dopaminergic stimulation without rapid peak concentrations.

Benefits of technology

The sulfamate derivatives demonstrate higher plasma exposure and solubility, lower peak concentrations, and increased conversion to the active compound, potentially reducing side effects and providing effective treatment for Parkinson's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
Patent Text Reader

Abstract

The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in the treatment of conditions where treatment with a dopamine agonist is therapeutically beneficial, and pharmaceutical compositions comprising the compounds of the invention. Compounds according to the invention have the formula (Id), wherein R1 and R2 are each independently selected from H and the following substituent (iii), wherein: * indicates the point of attachment to the oxygen, and R3 is selected from H and COR4, and R4 is selected from H and C1-C6 alkyl, with the proviso that R1 and R2 cannot both be H, or a pharmaceutically acceptable salt thereof. [Formula 1] JPEG2023552699000031.jpg29170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention provides compounds that are sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and their use in the treatment of Parkinson's disease and / or other conditions for which treatment with a dopamine agonist is therapeutically beneficial, such as restless legs syndrome, Huntington's disease, and Alzheimer's disease, as well as neuropsychiatric diseases and disorders such as schizophrenia, attention deficit hyperactivity disorder, and drug addiction. The present invention further provides pharmaceutical compositions comprising the compounds of the invention. [Background technology]

[0002] Parkinson's disease (PD) is a common neurodegenerative disorder that becomes more prevalent with age and affects an estimated 7 to 10 million people worldwide. It is a multifaceted disorder characterized by both motor and non-motor symptoms. Motor symptoms include resting tremor (tremor), bradykinesia / akinesia (slowness and lack of movement), muscle rigidity, postural stability, and gait dysfunction. Non-motor symptoms include neuropsychiatric disorders (e.g., depression, psychotic symptoms, anxiety, blunted affect, mild cognitive impairment, and dementia), as well as autonomic and sleep disorders (Poewe et al., Nature Review, (2017) vol. 3 article 17013:1-21).

[0003] A key hallmark of Parkinson's disease pathophysiology is the loss of pigmented dopaminergic neurons in the substantia nigra pars compacta, which provides dopaminergic innervation to the striatum and other brain regions. This progressive neurodegeneration leads to a decline in striatal dopamine levels, ultimately resulting in a series of changes in the basal ganglia circuitry and ultimately in the four cardinal motor features of Parkinson's disease. The primary targets of dopamine in the striatum consist of medium-spinous GABAergic neurons (MSNs) with topographically projecting processes that selectively express D1 or D2 receptors. GABAergic MSNs projecting to the lateral globus pallidus, also known as the striatopallidal "indirect pathway," express D2 receptors (MSN-2). GABAergic MSNs projecting to the substantia nigra pars reticulata and medial globus pallidus, also known as the striatonigral "direct pathway," express D1 receptors (MSN-1). The lack of dopamine due to neuronal loss leads to an imbalance in the activity of the two pathways, resulting in a significant decrease in thalamic and cortical output activity and ultimately motor dysfunction (Gerfen et al., Science (1990) 250:1429-32; Delong, (1990) Trends in Neuroscience 13:281-5; Alexander et Crutcher, (1990) Trends in Neuroscience 13:266-71 and for a review see Poewe et al., Nature Review (2017) vol. 3 article 17013:1-21).

[0004] The most effective treatment strategies available for patients with Parkinson's disease and aimed at controlling motor symptoms are primarily indirect and direct dopamine agonists. Classical and gold-standard therapy includes chronic oral administration of L-3,4-dihydroxyphenylalanine (L-DOPA), which is decarboxylated in the brain to form dopamine. Other approaches include the administration of dopamine receptor agonists, such as apomorphine, which acts on both D1 and D2 receptor subtypes, or pramipexole, ropinirole, and other agonists predominantly directed at the D2 receptor subtype. Due to the activation of both D1 and D2 receptor subtypes and the holistic rebalancing of the indirect-direct pathway (i.e., only D2 agonists reverse the dysfunction of the indirect pathway), optimal MR (relief of symptoms with movement) is achieved with the use of both L-DOPA and apomorphine.

[0005] L-DOPA and apomorphine, whose structures are shown below, are currently the most effective PD drugs in clinical use. [ka]

[0006] L-DOPA is a dopamine prodrug and remains the most effective drug for the treatment of motor Parkinson's disease. However, after several years of treatment (i.e., the honeymoon period), complications occur due to the inherent progression of the disease (i.e., the continued loss of dopaminergic neurons) and the poor pharmacokinetic (PK) profile of L-DOPA. These complications include 1) dyskinesia, which is an abnormal involuntary movement that occurs during the optimal "timely effect" of the drug, and 2) a period of fluctuation during which the positive effects of L-DOPA gradually decrease and symptoms reappear or worsen (Sprenger and Poewe, CNS Drugs (2013), 27: 259-272).

[0007] Direct dopamine receptor agonists can activate dopamine autoreceptors and postsynaptic dopamine receptors located on medium spiny neurons MSN-1 and MSN-2. Apomorphine belongs to a class of dopamine agonists that contain a 1,2-dihydroxybenzene (catechol) moiety. When combined with a phenethylamine motif, catecholamines often have low or no oral bioavailability, as is the case with apomorphine. Clinically, apomorphine is used to treat PD, albeit via parenteral delivery (typically intermittent subcutaneous administration or continuous daytime parenteral infusion via a pump). Animal studies have shown that transdermal delivery or implantation may provide potential administration forms for apomorphine. However, when apomorphine delivery from implants was studied in monkeys (Campbell et al., Chase Experimental Neurology (2005), 192:73-78), it was found that in most cases the animals had to be treated with the immunosuppressant dexamethasone to prevent local irritation and other complications after implantation. Alternative delivery strategies for apomorphine therapy in PD, such as inhaled and sublingual formulations, have been widely explored (see, e.g., Grosset et al., Acta Neurol Scand. (2013), 128:166-171 and Hauser et al., Movement Disorders (2016), Vol. 32(9):1367-1372).

[0008] An alternative to parenteral formulation of catecholamines involves the use of prodrugs that mask the free catechol hydroxyl group to allow oral administration. However, a known problem with developing prodrugs for clinical use is the difficulty associated with predicting conversion to the parent compound in humans.

[0009] Various ester prodrugs of catecholamines have been reported in the literature, including fully coated monopivaloyl esters of N-propyl-noraporphine (NPA) and apomorphine for duodenal delivery (WO 02 / 100377) and the diacetyl prodrug of the D1-like agonist adrogolide, A-86929 (Giardina and Williams; CNS Drug Reviews (2001), Vol. 7(3):305-316). Adrogolide undergoes extensive hepatic first-pass metabolism in men after oral administration, resulting in low oral bioavailability (approximately 4%). In PD patients, intravenous (IV) adrogolide has antiparkinsonian efficacy comparable to that of L-DOPA (Giardina and Williams; CNS Drug Reviews (2001), Vol. 7(3):305-316).

[0010] In addition to ester prodrugs of catecholamines, an alternative prodrug approach involves masking the two catechol hydroxyl groups as the corresponding methylene-dioxy (MDO) derivatives or diacetalyl derivatives. The principle of this prodrug is described, for example, in Campbell et al., Neuropharmacology (1982); 21(10):953-961, as well as U.S. Pat. No. 4,543,256, WO 2009 / 026934, and WO 2009 / 026935.

[0011] Another proposed approach to catecholamine prodrugs is the formation of enone derivatives, as proposed, for example, in WO 2001 / 078713 and Liu et al., Bioorganic Med. Chem. (2008), 16:3438-3444. For further examples of catecholamine prodrugs, see, for example, Sozio et al., Exp. Opin. Drug Disc. (2012); 7(5):385-406.

[0012] The compound (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diol, referred to below as Compound (I), is disclosed in International Publication No. WO 2009 / 026934. The trans isomer was previously disclosed by Liu et al., J. Med. Chem. (2006), 49:1494-1498, followed by Liu et al., Bioorganic Med. Chem. (2008), 16:3438-3444, including pharmacological data suggesting that the compound has low oral bioavailability in rats. The racemic compound was first disclosed by Cannon et al., J. Heterocyclic Chem. (1980); 17:1633-1636. [ka]

[0013] Compound (I) is a dopamine receptor agonist with mixed D1 and D2 activity. Different prodrug derivatives of Compound (I) are known in the art.

[0014] Liu et al., J. Med. Chem. (2006), 49:1494-1498 and Liu et al., Bioorganic Med. Chem. (2008), 16:3438-3444 disclose an enone derivative of formula (Ia), shown below, which was shown to be converted to the active compound (I) in rats. [ka]

[0015] WO 2009 / 026934 and WO 2009 / 026935 disclose two prodrug derivatives of compound (I), including (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline, a methyledioxy (MDO) derivative having the following formula (Ib): [ka]

[0016] The conversion of compound (Ib) to compound (I) in rat and human hepatocytes has been demonstrated in WO 2010 / 097092. Furthermore, the in vivo pharmacology of compounds (Ia) and (Ib) and the active "parent compound" (I) has been tested in various animal models of Parkinson's disease (WO 2010 / 097092). Both compound (I) and compounds (Ia) and (Ib) have been found to be effective, and it has been shown that compounds (Ia) and (Ib) are converted to compound (I) in vivo. All three compounds have been reported to have a longer duration of action than that observed for L-dopa and apomorphine.

[0017] Other prodrugs of Compound (I) disclosed in WO 2009 / 026934 and WO 2009 / 026935 are conventional ester prodrugs of formula (Ic) shown below: [ka]

[0018] WO2019101917 discloses further glucuronide conjugates of compound (I) as well as sulfate conjugates of compound (I) of the following formulae (Id-iia), (Id-iib) and (Id-iiab): [ka]

[0019] WO2019101917 proposes the use of the disclosed glucuronide and sulfate derivatives of Compound (I) as orally active prodrugs of Compound (I).

[0020] Other conjugates of Compound (I) are disclosed in WO2020234274, WO2020234275, WO2020234276 and WO2020234277.

[0021] Despite longstanding interest in this field, there remains a clear unmet need for the development of effective, well-tolerated, and orally active drugs for the treatment of PD. Prodrug derivatives of mixed D1 / D2 agonists with favorable PK profiles that can provide continuous dopaminergic stimulation may fulfill this unmet need.

[0022] Sulfamate derivatives as prodrug moieties have previously been proposed for estradiol, for example (Elger et al. J Steroid Biochem Mol Biol 55:395-403, 1995 and Elger et al. Reprod Fertil Dev 13:297-305, 2001). Summary of the Invention

[0023] The present invention relates to novel compounds for treating Parkinson's disease. More specifically, the present invention relates to novel sulfamate prodrug derivatives of the compound (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (Compound (I)). The compounds of the present invention have proven particularly useful for oral delivery of Compound (I), as demonstrated in the PK study in Example 2, where test compounds of the present invention are converted to Compound (I) in vivo.

[0024] Example 2 further demonstrates that test compounds (II) and (III) of the present invention provide plasma exposures in rats over a 24 hour period that are lower than the corresponding exposures observed for prior art compounds (Ia) and (Ib) and higher than the corresponding exposure for prior art compound (Ic), which was found not to be useful as a prodrug.

[0025] Furthermore, the observed C values ​​for Compound (I) after administration of both Compounds (II) and (III) in rats were lower than those achievable from administration of prior art Compounds (Ia) and (Ib) and prior art sulfate conjugate Compounds (Id-iia) and (Id-iib). Because the peak concentrations of Compound (I) expected to induce side effects are lower, higher doses of the compounds of the present invention may be administered to achieve higher total plasma concentrations of Compound (I) compared to those achievable from administration of Compounds (Ia) and (Ib). Compound (II) had an observed T of approximately 1 hour, which was faster than the prior art sulfate conjugate Compounds (Id-iia), (Id-iib), and (Id-iiab) and at the same time comparable to the prior art Compounds (Ia), (Ib), and (Ic).

[0026] Example 4 demonstrates that compounds (II) and (III) are converted to compound (I) upon incubation with human and rat liver S9 fractions (Figures 3 and 4). Furthermore, compounds (II) and (III) of the present invention had increased conversion to compound (I) upon incubation with human liver S9 compared to the prior art sulfate conjugate compounds (Id-iia) and (Id-iib) (Figure 3).

[0027] Furthermore, Example 3 demonstrates that the solubility of the compounds of the present invention, particularly Compound (II) and Compound (III), at pH 6 is higher than that of the corresponding prior art sulfate conjugate compounds (Id-iia) and (Id-iib). High solubility at pHs below pH 6.0 may be advantageous for facilitating absorption of the compounds after enteral administration.

[0028] In a first aspect, the present invention provides a compound of formula (Id): [ka] (In the formula, R1 and R2 each independently represent H or the following substituent (iii): [ka] (In the formula, * indicates the point of attachment to the oxygen, R3 is selected from H and COR4; R4 is selected from H and C1-C6 alkyl is selected from provided that R1 and R2 cannot both be H. or a pharmaceutically acceptable salt thereof.

[0029] In a preferred embodiment of the present invention, the compounds according to formula (Id) are those in which R3 is H.

[0030] In another preferred embodiment of the present invention, the compound according to formula (Id) is (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate of formula (II) and (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate of formula (III) [ka] and pharmaceutically acceptable salts thereof.

[0031] In another preferred embodiment, the compound according to the invention is in isolated form substantially free of the compound of formula (I). In another embodiment of the invention, the compound or a pharmaceutically acceptable salt thereof is in solid form.

[0032] A further aspect of the present invention provides pharmaceutically acceptable salts of compounds according to formula (Id).

[0033] A further aspect of the present invention provides a compound of formula (Id) or a pharmaceutically acceptable salt thereof for use as a pharmaceutical.

[0034] A further aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound according to formula (Id) or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. In a preferred embodiment, the pharmaceutical composition is an oral pharmaceutical composition, such as a tablet or capsule for oral administration.

[0035] A further aspect of the present invention provides a compound of formula (Id) or a pharmaceutically acceptable salt thereof for use in the treatment of a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction. In a preferred embodiment, the compound of formula (Id) or a pharmaceutically acceptable salt thereof is used in the treatment of Parkinson's disease.

[0036] A further aspect of the present invention provides the use of a compound of formula (Id) as defined above or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction. In a preferred embodiment, the medicament is for the treatment of Parkinson's disease.

[0037] A further aspect of the present invention provides a method of treating a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to formula (Id) or a pharmaceutically acceptable salt thereof. [Brief explanation of the drawings]

[0038] [Figure 1] Figure 1 shows PK profiles in Wistar rats obtained after oral administration according to Example 2. The profiles are based on the average plasma concentrations from three subjects per time point for each compound. X-axis: time (hours); Y-axis: plasma concentration (pg / mL) of compound (I) obtained after administration of compound (III). [Figure 2]Figure 1 shows PK profiles in Wistar rats obtained after oral administration according to Example 2. The profiles are based on the mean plasma concentrations from three subjects per time point for each compound. X-axis: time (hours); Y-axis: plasma concentration (pg / mL) of compound (I) obtained after administration of compound (II). [Figure 3] Figure 1 shows the in vitro conversion of compounds (II), (III), (Id-iia), and (Id-iib) to compound (I) in human liver S9. X-axis: time (minutes); Y-axis: increase in concentration of compound (I) (pg / mL) from the concentration at time = 0 minutes. ● indicates compound (III), ○ indicates compound (II), X indicates compound (Id-iia), and △ indicates compound (Id-iib). [Figure 4] Figure 1 shows the in vitro conversion of compounds (II), (III), (Id-iia), and (Id-iib) to compound (I) in rat liver S9. X-axis: time (minutes); Y-axis: increase in concentration of compound (I) (pg / mL) from the concentration at time = 0 minutes. ● indicates compound (III), ○ indicates compound (II), X indicates compound (Id-iia), and △ indicates compound (Id-iib). DETAILED DESCRIPTION OF THE INVENTION

[0039] Detailed Description of the Invention definition compound Reference to a compound encompassed by the present invention includes the free substance (e.g., free base or zwitterion) of the compound of the present invention, pharmaceutically acceptable salts, acid addition salts or base addition salts, etc. of the compound of the present invention, as well as polymorphic and amorphous forms of the compound of the present invention and its pharmaceutically acceptable salts. Furthermore, the compound of the present invention and its pharmaceutically acceptable salts can potentially exist in unsolvated and solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like. Both solvated and unsolvated forms are encompassed by the present invention.

[0040] Combination treatment As used herein in connection with the methods of the present invention comprising the combined administration of a therapeutically effective amount of a compound of formula (Id) with another compound that is useful in the treatment of a neurodegenerative disease or disorder, terms such as "combined use," "in combination with," and "a combination of" are intended to mean the simultaneous or sequential administration of a compound of formula (Id) in any order with said other compound.

[0041] pharmaceutically acceptable salts The compounds of the present invention are generally used as free substances or their pharmaceutically acceptable salts. When the compound of formula (Id) contains a free base, such salts can be prepared by conventional methods by treating a solution or suspension of the free base of formula (Id) with a molar equivalent of a pharmaceutically acceptable acid. Representative examples of suitable organic and inorganic acids are shown below.

[0042] In the context of this invention, pharmaceutically acceptable salts are intended to denote non-toxic, ie physiologically acceptable salts.

[0043] The term "pharmaceutically acceptable salts" includes pharmaceutically acceptable acid addition salts, which are salts formed with inorganic and / or organic acids at a nitrogen atom in the parent molecule. The acids may be selected from, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, malonic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, gentisic acid, saccharin, and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, naphthalene-2-sulfonic acid, 2-hydroxyethanesulfonic acid, and benzenesulfonic acid.

[0044] Other examples of acids and bases useful for forming pharmaceutically acceptable salts are described, for example, in Stahl and Wermuth (Eds), Handbook of Pharmaceutical Salts. Properties, Selection, and Use, Wiley-VCH2008.

[0045] Prodrug In the context of the present invention, the term "prodrug" or "prodrug derivative" refers to a compound that is converted into a pharmacologically active site in the body after administration to a living subject, such as a mammal, preferably a human. The conversion preferably occurs in a mammal, such as a mouse, rat, dog, minipig, rabbit, monkey, and / or human. In the context of the present invention, a "prodrug of the compound (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol" or a "prodrug of the compound of formula (I)" or a "prodrug of compound (I)" is understood to be a compound that is converted into the compound (4aR,10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol in the body after administration. Said administration may be by any conventional route of administration for pharmaceutical compositions known in the art, preferably oral administration.

[0046] In the context of the present invention, the terms "parent compound" and "parent molecule" refer to the pharmacologically active moiety obtained by conversion of the corresponding prodrug. For example, the "parent compound" of one of the compounds (Ia), (Ib), (Ic) or any of the compounds of the present invention according to formula (Id) (e.g., compounds (II), (III), and (V)) is understood to be the compound of formula (I).

[0047] substituent In the context of the present invention, ranges are indicated indiscriminately by a "-" (dash) or "~", for example, "C1-C6 alkyl" is equivalent to "C1 to C6 alkyl".

[0048] The term "alkyl" means a straight-chain (i.e., unbranched) or branched saturated hydrocarbon having from 1 to 6 carbon atoms. Examples of such groups include, but are not limited to, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-butyl, n-pentyl, isopentyl, and n-hexyl.

[0049] Pharmacokinetic Definitions and Abbreviations As used herein, "PK profile" is an abbreviation for "pharmacokinetic profile." The pharmacokinetic profiles and pharmacokinetic parameters described herein are based on plasma concentration-time data obtained for the compound of formula (I) following oral administration of the compounds of the invention using non-compartmental modeling. The omitted PK parameters are C max (maximum concentration);t max (C max arrival time);t 1 / 2 (Half-life); AUC 0~24 (area under the curve from time of administration to 24 hours post-dose), and "24 hour exposure" is the plasma concentration of the compound of formula (I) measured 24 hours post-dose.

[0050] Therapeutically effective dose In the context of the present invention, the term "therapeutically effective amount" of a compound of the present invention means an amount sufficient to alleviate, prevent, partially prevent, eliminate or delay the clinical symptoms of a given disease and its complications in a therapeutic intervention involving the administration of said compound. An amount adequate to achieve this is defined as a "therapeutically effective amount." The amount effective for each purpose will vary depending, for example, on the severity of the disease or injury and the weight and general condition of the subject. It will be understood that the determination of appropriate dosages can be achieved by constructing a matrix of values ​​and testing various points in that matrix using routine experimentation, which is well within the ordinary skill of a skilled physician.

[0051] In the context of the present invention, a "therapeutically effective amount" of a compound of the present invention means the amount of said compound of the present invention that, when administered to a mammal, preferably a human, preferably by the oral route, is capable of providing an amount of Compound (I) sufficient to alleviate, prevent, partially prevent, eliminate or delay the clinical symptoms of a given disease and its complications.

[0052] Treatment and Procedures In the context of the present invention, "treatment" or "therapy" is intended to refer to the management and care of a patient for the purpose of alleviating, arresting, partially arresting, eliminating or slowing the progression of the clinical symptoms of the disease. The patient to be treated is preferably a mammal, in particular a human being.

[0053] Pharmaceutical Formulations and Excipients Hereinafter, the term "excipient" or "pharmaceutically acceptable excipient" means pharmaceutical excipients such as, but not limited to, carriers, fillers, diluents, anti-adherents, binders, coatings, colorants, disintegrants, flavors, glidants, lubricants, preservatives, adsorbents, sweeteners, solvents, fillers and adjuvants.

[0054] Headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.

[0055] Description herein of any aspect of the invention or embodiments of the invention using terms such as "comprising," "having," "including," or "containing," with reference to an element, is intended to provide support for similar aspects of the invention or embodiments of the invention that "consist," "consist essentially of," or "substantially comprise" that particular element, unless specified otherwise or clearly contradicted by context (e.g., a composition described herein as comprising a particular element should be understood to also refer to a composition consisting of that element, unless specified otherwise or clearly contradicted by context).

[0056] The use of any and all examples or exemplary language (such as "for example," "for example," "example," "such as," and "per se") herein is intended merely to further clarify the invention and does not limit the scope of the invention unless otherwise specified.

[0057] It should be understood that the various aspects, embodiments, implementations and features of the invention described herein may be claimed separately or in any combination.

[0058] This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.

[0059] Compounds of the Invention The present inventors have identified novel sulfamate compounds that can function as prodrugs of the dual D1 / D2 agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol [Compound (I)] (see, e.g., WO 2009 / 026934).

[0060] Oral administration of representative Compounds (II) and (III) of the present invention in Wistar rats was found to provide systemic exposure of Compound (I) as measured by plasma concentrations of Compound (I), suggesting the utility of such compounds as orally active prodrugs of Compound (I).

[0061] For compounds tested in vivo, the dose was corrected by molecular weight to equate to a dose of 300 μg / kg of compound (Ib) corresponding to 287 μg / kg of compound (I).

[0062] It has previously been observed that oral administration of Compounds (Ia) and (Ib) to Wistar rats results in early and high peak plasma concentrations of Compound (I). Such high peak concentrations can be associated with dopaminergic side effects in humans, such as nausea, vomiting, and dizziness. In contrast, a slower absorption rate, accompanied by sustained exposure of Compound (I), was observed for Compound (II) of the present invention, preventing rapid peak concentrations. Furthermore, as shown in Example 2 herein, the plasma exposure of Compound (I) after oral administration of Compounds (II) and (III) in Wistar rats is higher than that observed for Compound (Ic), but still shows moderate exposure. However, due to the lower peak concentration of Compound (I) expected to induce side effects, higher doses of the compounds of the present invention can potentially be administered to achieve higher total plasma concentrations of Compound (I) compared to those achievable from administration of Compounds (Ia) and (Ib). When investigating the PK properties of compound (Ic), the inventors found that the plasma concentrations of compound (I) were very low, making compound (Ic) unsuitable as a prodrug of compound (I) for oral administration, confirming that the oral bioavailability of the compounds of the present invention is highly unpredictable.

[0063] The PK parameters for the PK study of compounds (II) and (III) in Wistar rats are listed in Table 2 and the PK profiles are shown in Figures 1 and 2.

[0064] Therefore, in conclusion, the compounds of the present invention are useful as orally available prodrugs of compound (I) and exhibit peak C activity as observed in the known prodrugs (Ia) and (Ib). max It has been confirmed in rats that the PK profile provides a significantly higher AUC of Compound (I) than Compound (Ic), avoiding the above-mentioned problems. The compounds of the present invention are orally administered to one or more subjects, for example, animals, such as rats, minipigs, monkeys, or humans (rat being the preferred subject), and the concentration of Compound (I) in plasma is measured as described in Example 2 or Example 3 below, thereby determining the C maxand PK profiles can be measured. Thus, in one embodiment of the present invention, the compound of formula (Id) exhibits peak C , which is observed for the known prodrugs (Ia) and (Ib). max and has a confirmed PK profile that avoids the above-mentioned problems and results in a higher AUC for Compound (I) than for Compound (Ic). Accordingly, in one embodiment of the present invention, the compound of Formula (Id) has a Cmax of greater than about 90 pg / mL, for example, in the range of about 90 to about 600 pg / mL, for example, in the range of about 90 to about 400 pg / mL, for example, in the range of about 100 to 200 pg / mL, or in the range of about 200 to about 300 pg / mL, or in the range of about 300 to about 400 pg / mL. In another embodiment of the present invention, the Cmax is less than 3000 pg / mL, more preferably less than 1000 pg / mL, for example, in the range of about 50 to about 500 pg / mL.

[0065] In another embodiment of the present invention, the compound of formula (Id) is administered in an amount of 1000 pg or more measured over a 24 hour period. * h / mL or more, e.g., about 1500 to about 5000 pg * h / mL range, e.g., approximately 1500-4000 pg * h / mL range, e.g., approximately 1600 pg * h / mL, or e.g., about 1700 pg * h / mL, or, for example, about 1800 pg * h / mL, or e.g., about 1900 pg * h / mL, or, for example, about 2000 pg * h / mL, or, for example, about 2100 pg * h / mL, or, for example, about 2200 pg * h / mL, or, for example, about 2300 pg * h / mL, or, for example, about 2400 pg * h / mL, or, for example, about 2500 pg * h / mL, or, for example, about 2600 pg * h / mL, or, for example, about 2700 pg * h / mL, or, for example, about 2800 pg * h / mL, or, for example, about 2900 pg * h / mL, or, for example, about 3000 pg *h / mL, or for example, about 3100 pg * h / mL, or for example, about 3200 pg * h / mL, or for example, about 3300 pg * h / mL, or for example, about 3400 pg * h / mL, or for example, about 3500 pg * h / mL, or for example, about 3600 pg * h / mL, or, for example, about 3700 pg * h / mL, or, for example, about 3800 pg * h / mL, or for example, about 3900 pg * h / mL, or for example, about 4000 pg * h / mL, or for example, about 4100 pg * h / mL, or, for example, about 4200 pg * h / mL, or for example, about 4300 pg * h / mL, or for example, about 4400 pg * h / mL, or, for example, about 4500 pg * h / mL, or for example, about 4600 pg * h / mL, or for example, about 4700 pg * h / mL, or, for example, about 4800 pg * h / mL, or for example, about 4900 pg * h / mL, or, for example, about 5000 pg * It has an AUC of h / mL.

[0066] In a more preferred embodiment of the invention, the compound of formula (Id) has a Cmax of greater than about 90 pg / mL, for example in the range of about 90 to about 600 pg / mL, and a Cmax of about 1500 to about 5000 pg / mL measured over 24 hours. * h / mL range, e.g., approximately 1500-4000 pg * It has an AUC in the range of h / mL.

[0067] Example 4 demonstrates that compounds (II) and (III) are converted to compound (I) upon incubation with human and rat liver S9 fractions (Figures 3 and 4). Furthermore, compounds (II) and (III) of the present invention were demonstrated to have increased conversion to compound (I) upon incubation with human liver S9 compared to prior art sulfate conjugate compounds (Id-iia) and (Id-iib) (Figure 3).

[0068] Thus, in one embodiment of the present invention, compound (Id) has increased conversion to compound (I) after incubation with human liver S9 compared to prior art sulfate conjugate compounds (Id-iia) and (Id-iib). In a more specific embodiment of the present invention, the method described in Example 4 or other compounds of formula (Id) known in the prior art have increased conversion to compound (I) compared to prior art sulfate conjugate compounds (Id-iia) and (Id-iib), as measured using other equivalent methods.

[0069] Furthermore, Example 3 demonstrates that the solubility of the compounds of the present invention, particularly Compound (II) and Compound (III), at pH 6.0 is higher than that of the corresponding prior art compounds (Id-iia) and (Id-iib), see Table 3. The solubility of the compounds of the present invention can be measured, for example, by the method described in Example 3, by dissolving the compound in a solution, for example, a solution containing a buffer at an appropriate acidic pH, such as a phosphate buffer at pH 6.0.

[0070] Thus, in one embodiment of the present invention, the compound of formula (Id) has increased solubility at acidic pH compared to the prior art sulfate conjugate compounds (Id-iia) and (Id-iib), e.g., a measured solubility at pH 6.0 of greater than about 0.035 mg / mL, e.g., in the range of about 0.035 to about 0.01 mg / mL, or greater than about 0.1 mg / mL, e.g., in the range of about 0.1 to about 1.0 mg / mL, e.g., about 0.2 mg / mL, or about 0.3 mg / mL, or about 0.4 mg / mL, or about 0.5 mg / mL, or about 0.6 mg / mL, or about 0.7 mg / mL, or about 0.8 mg / mL, or about 0.9 mg / mL, or about 1.0 mg / mL, or greater than about 1.0 mg / mL, e.g., in the range of about 1.0 to about 5 mg / mL.

[0071] Thus, one aspect of the present invention provides a sulfamate derivative of Compound (I) or a pharmaceutically acceptable salt thereof.

[0072] Thus, in a first aspect, the present invention provides a compound of formula (Id): [ka] (In the formula, R1 and R2 each independently represent H or the following substituent (iii): [ka] (In the formula, * indicates the point of attachment to the oxygen, R3 is selected from H and COR4; R4 is C1-C6 alkyl. is selected from provided that R1 and R2 cannot both be H. or a pharmaceutically acceptable salt thereof.

[0073] Thus, in one embodiment of the present invention, the present invention provides a compound according to formula (Id) (wherein at least one of R1 or R2 is substituent (iii)), such as a compound according to formula (Id) (wherein R1 is substituent (iii) and R2 is H); or for example a compound according to formula (Id) (wherein R1 is H and R2 is substituent (iii)); or a compound according to formula (Id) (wherein both R1 and R2 are substituent (iii)); or a pharmaceutically acceptable salt thereof.

[0074] In a preferred embodiment of the present invention, the compound of the present invention is a compound according to formula (Id) (wherein R1 is substituent (iii) and R2 is H); or a compound according to formula (Id) (wherein R1 is H and R2 is substituent (iii)), or a pharmaceutically acceptable salt thereof.

[0075] In one preferred embodiment of the present invention, there is provided a compound according to formula (Id) wherein R3 is H, or a pharmaceutically acceptable salt thereof.

[0076] In another embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is selected from the group consisting of H and C1-C6 alkyl. Such compounds include compounds according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is selected from the group consisting of hydrogen, methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-butyl, n-pentyl, isopentyl, and n-hexyl. In a more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is selected from the group consisting of methyl, ethyl, 1-propyl, and 2-propyl.

[0077] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) wherein R3 is COR4 and R4 is H, or a pharmaceutically acceptable salt thereof.

[0078] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is methyl.

[0079] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is ethyl.

[0080] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is 1-propyl.

[0081] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is 2-propyl.

[0082] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is 1-butyl.

[0083] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is 2-butyl.

[0084] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is 2-methyl-2-propyl.

[0085] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is 2-methyl-1-butyl.

[0086] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is n-pentyl.

[0087] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is isopentyl.

[0088] In an even more specific embodiment of the present invention, there is provided a compound according to formula (Id) or a pharmaceutically acceptable salt thereof, wherein R3 is COR4 and R4 is n-hexyl.

[0089] In a specific embodiment of the present invention, the compound of the present invention is a compound of formula (Id) (wherein at least one of R1 and R2 is substituent (iii) and R3 is H), or a pharmaceutically acceptable salt thereof. Thus, in one embodiment of the present invention, the compound of the present invention is a compound of the following formula (II): [ka] (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate, Formula (III): [ka] (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate, Formula (IV): [ka] (4aS,10aR)-4a-amino-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(sulfamate) and a pharmaceutically acceptable salt of any one of these compounds.

[0090] In a specific embodiment of the present invention, the compound of the present invention is a compound of formula (Id) (wherein at least one of R1 and R2 is substituent (iii) and R3 is H), or a pharmaceutically acceptable salt thereof. Thus, in one embodiment of the present invention, the compound of the present invention is a compound of the following formula (II): [ka] (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate, (III) of the following: [ka] (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate, Formula (V): [ka] (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(sulfamate) and a pharmaceutically acceptable salt of any one of these compounds.

[0091] In a preferred embodiment of the present invention, the compound of the present invention is a compound of formula (Id) or a pharmaceutically acceptable salt thereof, wherein both R and R are substituent (iii) and R is H. Thus, in a preferred embodiment of the present invention, the compound of formula (Id) is (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(sulfamate).

[0092] Example 2 demonstrates that sulfamate-conjugated compounds (II) and (III), which are examples of compounds of formula (Id) where one of R1 and R2 is substituent (iii) and R3 is H, are converted to compound (I) in vivo.

[0093] Thus, in a preferred embodiment of the present invention, the compound of the present invention is a compound of formula (Id) (wherein one of R1 and R2 is H and the other is substituent (iii), and R3 is H), or a pharmaceutically acceptable salt thereof.

[0094] Thus, in a preferred embodiment of the present invention, the compound according to formula (Id) has the following formula (II): [ka] (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate, The following formula (III) [ka] (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate and a pharmaceutically acceptable salt of any of these compounds.

[0095] Therefore, in a further preferred embodiment of the present invention, the compound according to formula (Id) has the following formula (II): [ka] or a pharmaceutically acceptable salt thereof.

[0096] Therefore, in another preferred embodiment of the present invention, the compound according to formula (Id) has the following formula (III): [ka] or a pharmaceutically acceptable salt thereof.

[0097] One embodiment of the present invention provides a pharmaceutically acceptable salt of a compound according to formula (Id). In one embodiment, the pharmaceutically acceptable salt is an acid addition salt as defined herein above.

[0098] Determination of the purity of the compounds of the present invention can be determined using different chromatographic methods, such as LC / MS methods known in the art, optionally in conjunction with mass spectrometry, such as those described in the Examples section.

[0099] In one embodiment of the present invention, the compound according to formula (Id) or a pharmaceutically acceptable salt thereof is in isolated form, substantially free of compounds of formula (I).

[0100] In one embodiment of the invention, the compound according to formula (Id) or a pharmaceutically acceptable salt thereof is in isolated form of greater than 90% purity, such as about 90-99.99% purity, for example 95% purity, such as 96% purity, for example 97% purity, such as 98% purity, for example 99% purity, for example 99.5% purity.

[0101] The compounds of the present invention may exist in different forms such as amorphous or crystalline forms.

[0102] In one embodiment of the invention, the compound according to formula (Id) or a pharmaceutically acceptable salt thereof is in solid form. In an even more preferred embodiment of the invention, the compound of formula (Id) or a pharmaceutically acceptable salt thereof is in crystalline form.

[0103] The solid form may also be an amorphous solid form. Thus, in one embodiment of the present invention, the compound of formula (Id) is in an amorphous solid form.

[0104] Also included in the present invention are isotopically labeled compounds analogous to the compounds claimed in formula (Id), in which one or more atoms are represented by an atom of the same element having an atomic mass or mass number different from the atomic mass or mass number usually found in nature (e.g., 2H, 3H, 11C, 13C, 15N, etc.) Particular mention is made of 2H-substituted compounds, i.e., compounds in which one or more H atoms are represented by deuterium.

[0105] In one embodiment of the present invention, one or more of the hydrogen atoms of the compound of formula (Id) are represented by deuterium. It is recognized that in most synthetic compounds, elements are present at their natural isotopic abundance, and inherent incorporation of deuterium occurs. However, the natural isotopic abundance of hydrogen isotopes such as deuterium is insignificant (about 0.015%) relative to the degree of stable isotopic substitution of the compounds presented herein.

[0106] Pharmaceutical Composition Another aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (Id) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0107] In a preferred embodiment, the pharmaceutical composition comprises a compound of formula (Id) selected from the group consisting of compound (II), compound (III) and pharmaceutically acceptable salts thereof.

[0108] A further aspect of the present invention is a process for preparing a pharmaceutical composition comprising a compound of formula (Id) or a pharmaceutically acceptable salt thereof, more preferably the process for preparing a pharmaceutical composition comprising a compound selected from the group consisting of compound (II) and compound (III) herein or a pharmaceutically acceptable salt thereof.

[0109] Pharmaceutical compositions according to the present invention can be formulated using pharmaceutically acceptable excipients according to conventional techniques, such as those disclosed in Remington, The Science and Practice of Pharmacy, 22nd edition (2013), Edited by Allen, Loyd V., Jr.

[0110] The pharmaceutical composition comprising the compound of the present invention is preferably a pharmaceutical composition for oral administration.The pharmaceutical composition for oral administration includes solid oral dosage forms such as tablets, capsules, powders and granules; and liquid oral dosage forms such as solutions, emulsions, suspensions and syrups, and powders and granules that are dissolved or suspended in suitable liquids.

[0111] Solid oral dosage forms can be provided as individual units (e.g., tablets or hard or soft capsules), each containing a predetermined amount of the active ingredient, preferably one or more suitable excipients. Where appropriate, the solid dosage form can be prepared with a coating, such as an enteric coating, or can be formulated to provide controlled release of the active ingredient, such as delayed or sustained release, according to methods well known in the art. Where appropriate, the solid dosage form can be a dosage form that disintegrates in saliva, such as, for example, an orally dispersible tablet.

[0112] In a preferred embodiment of the present invention, the pharmaceutical composition is a composition for oral administration and is selected from the group consisting of tablets and capsules.

[0113] Examples of excipients suitable for solid oral dosage forms include, but are not limited to, microcrystalline cellulose, corn starch, lactose, mannitol, povidone, croscarmellose sodium, sucrose, cyclodextrin, talcum, gelatin, pectin, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose. Similarly, solid formulations may contain excipients for delayed or sustained release formulations known in the art, such as glyceryl monostearate or hypromellose. When solid materials are used for oral administration, the formulation may be prepared, for example, by mixing the active ingredient with a solid excipient and then compressing the mixture using conventional tableting equipment, or the formulation may be placed in a hard capsule in the form of, for example, a powder, pellet, or minitablet. The amount of solid excipient varies widely but typically ranges from about 25 mg to about 1 g per dosage unit.

[0114] Liquid oral dosage forms can be provided, for example, as elixirs, syrups, oral drops, or liquid-filled capsules. Liquid oral dosage forms can also be provided as powders for solution or suspension in aqueous or non-aqueous liquids. Examples of excipients suitable for liquid oral dosage forms include, but are not limited to, ethanol, propylene glycol, glycerol, polyethylene glycol, poloxamer, sorbitol, polysorbate, monoglycerides and diglycerides, cyclodextrin, coconut oil, palm oil, and water. Liquid oral dosage forms can be prepared, for example, by dissolving or suspending the active ingredient in an aqueous or non-aqueous liquid, or by incorporating the active ingredient into an oil-in-water or water-in-oil liquid emulsion.

[0115] Additional excipients such as colorants, flavors and preservatives may be used in both solid and liquid oral formulations.

[0116] Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous solutions, dispersions, suspensions, or emulsions for injection or infusion, concentrates for injection or infusion, and sterile powders to be dissolved in a sterile solution or dispersion for injection or infusion before use. Examples of excipients suitable for parenteral formulations include, but are not limited to, water, coconut oil, palm oil, and cyclodextrin solutions. Aqueous formulations should be appropriately buffered, if necessary, and rendered isotonic with sufficient saline or glucose.

[0117] Other types of pharmaceutical compositions include suppositories, inhalants, creams, gels, transdermal patches, implants, and formulations for buccal or sublingual administration.

[0118] Excipients used in pharmaceutical formulations should be compatible with the intended route of administration and with the active ingredient.

[0119] Uses and Treatment Methods Another aspect of the present invention provides a compound according to formula (Id) for use as a pharmaceutical and a method of treatment in which a compound according to formula (Id) is administered to a subject in need thereof.

[0120] Medical Indications and Conditions for Treatment The compounds of the present invention are conjugated versions of dopamine agonists and, therefore, the compounds of the present invention are intended for use in the treatment of neurodegenerative diseases and disorders such as Parkinson's disease and / or other conditions where treatment with a dopamine agonist would be therapeutically beneficial.

[0121] Therapeutic indications for which treatment with dopamine agonists is therapeutically beneficial include a variety of central nervous system disorders characterized by motor and / or non-motor disorders and in which part of the underlying pathophysiology is dysfunction of striatal-mediated circuitry. Such functional disorders are also found in neurodegenerative disorders such as, but not limited to, Parkinson's disease (PD), restless legs syndrome, Huntington's disease, and Alzheimer's disease, and / or neuropsychiatric disorders such as schizophrenia, attention deficit hyperactivity disorder, and drug addiction.

[0122] Thus, in one embodiment of the present invention, the compound according to formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention is used for the treatment of a neurodegenerative disease or disorder or a neuropsychiatric disease or disorder.

[0123] More specifically, in one embodiment of the present invention, the compound according to formula (Id) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to the invention is used for the treatment of a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0124] The present invention also provides a method for treating a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction, which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound according to formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention.

[0125] Compounds suitable for oral administration have the potential to provide a new treatment paradigm for Parkinson's disease. Thus, in a preferred embodiment of the present invention, the compound of the present invention according to formula (Id) or a pharmaceutically acceptable salt thereof or the pharmaceutical composition according to the present invention is used in a method for treating Parkinson's disease.

[0126] In addition to neurodegenerative diseases and disorders, other conditions in which increased dopaminergic turnover may be beneficial include improved mental function, including various aspects of cognition. It may also have a positive effect on depressed patients and may be used as an appetite suppressant to treat obesity and drug addiction. It may potentially improve negative, positive, and cognitive symptoms of microcerebrovascular disorder (MBD), narcolepsy, attention deficit hyperactivity disorder, and schizophrenia.

[0127] Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) are other indications that are clinically treated with dopamine agonists.In addition, sexual impotence, erectile dysfunction, SSRI-induced sexual dysfunction, ovarian hyperstimulation syndrome (OHSS) and certain pituitary tumors (prolactinomas) may also be improved by treating with dopamine agonists.Dopamine is involved in the regulation of the circulatory system and renal system, therefore, renal failure and hypertension may be considered as alternative indications for the compounds of the present invention.

[0128] dose The compounds of the present invention according to formula (Id) can be used for treatment in various dosages as required for therapy. Thus, in one embodiment, they are administered in an amount of about 0.0001 to about 5 mg / kg body weight per day. In particular, the daily dose can range from 0.001 to about 2 mg / kg body weight per day. The exact dosage will vary depending on the frequency and mode of administration, the sex, age, weight, and general condition of the subject to be treated, the nature and severity of the condition to be treated, any accompanying diseases to be treated, the desired effect of treatment, and other factors known to those skilled in the art.

[0129] A typical oral dosage for an adult is in the range of 0.01 to 100 mg / day of a compound of the invention, such as 0.05 to 50 mg / day, 0.1 to 10 mg / day or 0.1 to 5 mg / day or 1 to 10 mg / day, or 10 to 15 mg / day, 15 to 25 mg / day, 25 to 35 mg / day, 35 to 45 mg / day, or for example 55 to 65 mg / day, or 70 to 85 mg / day, or 80 to 95 mg / day.

[0130] Conveniently, the compounds of the invention are administered in a unit dosage form containing said compound in an amount of about 0.01 to 100 mg, for example about 0.01 to 50 mg, for example 0.05 mg, 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg or up to 50 mg.

[0131] Administration route Pharmaceutical compositions comprising compounds of formula (Id), either as the sole active compound or in combination with other active compounds, may be specially formulated for administration by any suitable route, such as oral, rectal, nasal, buccal, sublingual, pulmonary, transdermal and parenteral (e.g., subcutaneous, intramuscular and intravenous) routes. In the context of the present invention, the oral route is the preferred route of administration.

[0132] It is understood that the route will vary depending on the general condition and age of the subject being treated, the nature of the condition being treated and the active ingredient.

[0133] A further aspect of the present invention relates to a method for treating a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction, which method comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention.

[0134] In a preferred embodiment of the invention, the method of treatment is a method of treating a neurodegenerative disease or disorder, even more preferably a method of treating Parkinson's disease.

[0135] A further aspect of the invention relates to the use of a compound according to formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction.

[0136] In a preferred embodiment of the invention, the compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention is used in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder, more preferably for the treatment of Parkinson's disease.

[0137] In one embodiment of the present invention, the compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention is used as the sole active compound as a stand-alone therapy.

[0138] In one embodiment of the present invention, the compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention is used as a stand-alone treatment for a neurodegenerative disease or disorder, such as Parkinson's disease.

[0139] combination In another embodiment of the present invention, the compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the present invention may be used in combination with other agents useful in the treatment of neurodegenerative diseases or disorders, such as Parkinson's disease.

[0140] In one embodiment of the present invention, a compound selected from the group consisting of compounds (II), (III), and (IV), or a pharmaceutically acceptable salt of any one of these compounds, is used in conjunction with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease. In one embodiment of the present invention, a compound selected from the group consisting of compounds (II), (III), and (V), or a pharmaceutically acceptable salt of any one of these compounds, is used in conjunction with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease. In an even more specific embodiment, a compound selected from the group consisting of compounds (II) and (III), or a pharmaceutically acceptable salt of any one of these compounds, is used in conjunction with another agent useful for treating a neurodegenerative disease or disorder, such as Parkinson's disease.

[0141] The two compounds can be administered simultaneously or with an interval between the administration of the two compounds. The two compounds can be administered as part of the same pharmaceutical formulation or composition or in separate pharmaceutical formulations or compositions. The two compounds can be administered on the same day or on different days. They can be administered by the same route, such as oral administration, subcutaneous injection, transdermal administration, depot administration, intramuscular injection, or intravenous injection, or by different routes, such as one compound being administered orally or via a depot and the other compound being administered by injection. The two compounds can be administered according to the same dosing schedule or interval, such as once or twice daily, weekly, or monthly, or according to different dosing schedules, such as one being administered once daily and the other twice daily, weekly, or monthly.

[0142] In some cases, the patient being treated may already be undergoing treatment with one or more other compounds useful in the treatment of neurodegenerative diseases or disorders when treatment with the compound of formula (Id) or a pharmaceutically acceptable salt thereof is initiated. In other cases, the patient may already be undergoing treatment with the compound of formula (Id) when treatment with the one or more other compounds useful in the treatment of neurodegenerative diseases or disorders is initiated. In other cases, treatment with the compound of formula (Id) and treatment with the one or more other compounds useful in the treatment of neurodegenerative diseases or disorders are initiated simultaneously.

[0143] The compounds of the present invention or pharmaceutically acceptable salts thereof, or pharmaceutical compositions according to the present invention may be used in combination with one or more compounds commonly used in the treatment of neurodegenerative diseases or disorders, such as Parkinson's disease. Thus, in one embodiment of the present invention, the compound of formula (Id) or pharmaceutically acceptable salts thereof, or pharmaceutical compositions according to the present invention, are used in combination with a compound selected from the group consisting of MAO-B inhibitors such as L-DOPA, droxidopa, foliglax, selegiline, or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, antiglutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil, or galantamine, and antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole, or brexpiprazole.

[0144] In one embodiment of the present invention, a compound selected from the group consisting of compounds (II), (III), and (IV), or a pharmaceutically acceptable salt of any one of these compounds, is used in combination with a compound selected from the group consisting of an MAO-B inhibitor such as L-DOPA, droxidopa, foliglax, selegiline, or rasagiline, a COMT inhibitor such as entacapone or tolcapone, an adenosine 2a antagonist such as istradefylline, an antiglutamate agent such as amantadine or memantine, an acetylcholinesterase inhibitor such as rivastigmine, donepezil, or galantamine, and an antipsychotic such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole, or brexpiprazole.

[0145] In one embodiment of the present invention, a compound selected from the group consisting of compounds (II), (III), and (V), or a pharmaceutically acceptable salt of any one of these compounds, is used in combination with a compound selected from the group consisting of an MAO-B inhibitor such as L-DOPA, droxidopa, foliglax, selegiline, or rasagiline, a COMT inhibitor such as entacapone or tolcapone, an adenosine 2a antagonist such as istradefylline, an antiglutamate agent such as amantadine or memantine, an acetylcholinesterase inhibitor such as rivastigmine, donepezil, or galantamine, and an antipsychotic such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole, or brexpiprazole.

[0146] In an even more specific embodiment, a compound selected from the group consisting of compounds (II) and (III), or a pharmaceutically acceptable salt of any one of these compounds, is used in combination with a compound selected from the group consisting of L-DOPA, droxidopa, foliglax, MAO-B inhibitors such as selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, antiglutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, and antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or brexpiprazole.

[0147] In addition to small molecules, compounds combined with the compounds of the present invention may also include emerging biologic approaches in the treatment of neurodegenerative diseases or disorders, such as, for example, antibodies targeting alpha-synuclein, Tau, or A-beta proteins.

[0148] Thus, in one embodiment of the present invention, the compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention is used in conjunction with other agents for the treatment of Parkinson's disease, such as a compound selected from the group consisting of MAO-B inhibitors such as L-DOPA, droxidopa, foliglax, selegiline or rasagiline, COMT inhibitors such as entacapone or tolcapone, adenosine 2a antagonists such as istradefylline, antiglutamate agents such as amantadine or memantine, acetylcholinesterase inhibitors such as rivastigmine, donepezil or galantamine, and antipsychotics such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole or brexpiprazole; or an antibody targeting alpha-synuclein, Tau or A-beta protein.

[0149] In one embodiment of the present invention, a compound selected from the group consisting of compounds (II), (III), and (IV), or a pharmaceutically acceptable salt of any one of these compounds, is used in combination with a compound selected from the group consisting of an MAO-B inhibitor such as L-DOPA, droxidopa, foliglax, selegiline, or rasagiline, a COMT inhibitor such as entacapone or tolcapone, an adenosine 2a antagonist such as istradefylline, an antiglutamate agent such as amantadine or memantine, an acetylcholinesterase inhibitor such as rivastigmine, donepezil, or galantamine, and an antipsychotic such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole, or brexpiprazole; or an antibody targeting alpha-synuclein, Tau, or A-beta protein.

[0150] In one embodiment of the present invention, a compound selected from the group consisting of compounds (II), (III), and (V), or a pharmaceutically acceptable salt of any one of these compounds, is used in combination with a compound selected from the group consisting of an MAO-B inhibitor such as L-DOPA, droxidopa, foliglax, selegiline, or rasagiline, a COMT inhibitor such as entacapone or tolcapone, an adenosine 2a antagonist such as istradefylline, an antiglutamate agent such as amantadine or memantine, an acetylcholinesterase inhibitor such as rivastigmine, donepezil, or galantamine, and an antipsychotic such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole, or brexpiprazole; or an antibody targeting alpha-synuclein, Tau, or A-beta protein.

[0151] In even more specific embodiments, a compound selected from the group consisting of compounds (II) and (III), or a pharmaceutically acceptable salt of any one of these compounds, is used in conjunction with a compound selected from the group consisting of an MAO-B inhibitor such as L-DOPA, droxidopa, foliglax, selegiline, or rasagiline, a COMT inhibitor such as entacapone or tolcapone, an adenosine 2a antagonist such as istradefylline, an antiglutamate agent such as amantadine or memantine, an acetylcholinesterase inhibitor such as rivastigmine, donepezil, or galantamine, and an antipsychotic such as quetiapine, clozapine, risperidone, pimavanserin, olanzapine, haloperidol, aripiprazole, or brexpiprazole; or an antibody targeting alpha-synuclein, Tau, or A-beta protein.

[0152] In one embodiment, the compound according to Formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the invention is used as the sole medicament for the treatment of a patient, hi one embodiment, the compound according to Formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the invention is used to treat a patient who has not been previously treated with another drug selected from the list above.

[0153] One aspect of the present invention provides the use of a compound of formula (Id) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to the invention in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder, such as Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or for the treatment of a neuropsychiatric disease or disorder, such as schizophrenia, attention deficit hyperactivity disorder or drug addiction. In a preferred embodiment, the medicament is for the treatment of Parkinson's disease.

[0154] Exemplary Compounds of the Invention

[0155] [Table 1] [Example]

[0156] Example 1 - Preparation of Compounds of the Invention The compounds of the present invention of general formula Id (wherein R1 and R2 are as defined above) can be prepared by the methods shown in the following examples. In the methods described, it is possible to make use of variations or modifications that are known per se to chemists of ordinary skill in the art or that will be apparent to those skilled in the art. Furthermore, other methods for preparing the compounds of the present invention will be readily apparent to those skilled in the art in light of the following examples.

[0157] The starting materials used herein are commercially available or can be prepared by conventional methods known in the art, for example, methods described in standard reference books such as "Compendium of Organic Synthetic Methods, Vol. I-XII" (Wiley-Interscience Publishing). Preferred methods include, but are not limited to, the following methods:

[0158] More specifically, the compound (4aR,10aR)-1-n-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinoline-6,7-diol can be prepared, for example, according to the instructions in WO 2009 / 026934.

[0159] The schemes represent methods useful for synthesizing compounds of the invention. They are not intended to limit the scope of the invention in any way.

[0160] Compound (II) (4aR,10aR)-6-Hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate [ka] To a stirred solution of chlorosulfonyl isocyanate (4.07 g, 28.6 mmol) in acetonitrile (20 mL) was added formic acid (1.32 g, 28.7 mmol) dropwise at room temperature. The resulting mixture was stirred overnight at room temperature. To the above mixture was added (4aR,10aR)-1-n-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinoline-6,7-diol (1.50 g, 5.7 mmol) and N,N-dimethylacetamide (10 mL). The resulting mixture was stirred at room temperature for an additional 6 hours. The reaction was quenched by the addition of ammonium hydroxide solution (10 mL) at room temperature. The resulting mixture was concentrated under reduced pressure.

[0161] Preparative HPLC (column: XBridge Shield RP18 OBD column, 19 * The residue was purified by HPLC using a 250 mm, 10 μm column; mobile phase A: water (10 mMol / L NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 17% B to 32% B in 10 min; 220 nm; retention time: 9.10 min) to give (4aR,10aR)-6-hydroxy-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinolin-7-ylsulfamate (406 mg).

[0162] LC-MS equipment and protocol: Shimadzu LCMS-2020 equipped with a Shim-Pack XR-ODS C18, L=50 mm, D=3.0 mm column operated at 40° C. Mobile phase A: 0.05% TFA in water; Mobile phase B: 0.05% TFA in acetonitrile. Flow rate: 1.2 mL / min. gradient: 0~3.2 minutes:A:B95:5; 3.2~3.7 minutes:A:B1:1; 3.7-4.75 min: A:B 0:1; 4.75~5.0 minutes: A:B95:5. LC-MS(MH+): m / z=341.2 Retention time (min)=1.523 1H NMR(400MHz,DMSO)δ 7.01-6.99(d,1H),6.62-6.60(d,1H),2.94-2..911(m,1H),2.85-2.79(m,1H),2.72-2.66(m,1H),2.51-2.49(m,1H) ,2.45-2.28(m,1H),2.16-2.06(m,3H),1.85-1.82(m,1H),1.64-1.40(m,5H),1.09-1.06(m,1H),0.86-0.83(t,3H).

[0163] Compound (III) (4aR,10aR)-7-Hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate [ka] To a stirred solution of chlorosulfonyl isocyanate (4.07 g, 28.6 mmol) in acetonitrile (20 mL) was added formic acid (1.32 g, 28.7 mmol) dropwise at room temperature. The resulting mixture was stirred overnight at room temperature. To the above mixture were added (4aR,10aR)-1-n-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinoline-6,7-diol (1.50 g, 5.7 mmol) and N,N-dimethylacetamide (10 mL). The resulting mixture was stirred at room temperature for an additional 6 hours. The reaction was quenched by adding ammonium hydroxide solution (10 mL) at room temperature. The resulting mixture was concentrated under reduced pressure. Preparative HPLC (column: XBridge Shield RP18 OBD column, 19 * The residue was purified by HPLC (250 mm, 10 μm; mobile phase A: water (10 mMol / L NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 17% B to 32% B in 10 min; 254 nm; retention time: 8.18 min) to give (4aR,10aR)-7-hydroxy-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinolin-6-ylsulfamate (297 mg).

[0164] LC-MS equipment and protocol: Shimadzu LCMS-2020 equipped with a Shim-Pack XR-ODS C18, L=50 mm, D=3.0 mm column operated at 40° C. Mobile phase A: 0.05% TFA in water; Mobile phase B: 0.05% TFA in acetonitrile. Flow rate: 1.2 mL / min. gradient: 0~3.2 minutes:A:B95:5; 3.2~3.7 minutes:A:B1:1; 3.7-4.75 min: A:B 0:1; 4.75~5.0 minutes: A:B95:5. LC-MS(MH+): m / z=341.2 Retention time (min)=1.42 1 H NMR(400MHz,DMSO)δ 6.82-6.84(d,1H),6.73-6.70(d,1H),3.12-3.07(m,1H),2.95-2.90(m,1H),2.72-2.63(m,1H),2.53-2.51(m,1H) ,2.50-2.43(m,1H),2.41-2.32(m,3H),1.82-1.79(m,1H),1.64-1.39(m,5H),1.07-1.02(m,1H),0.86-0.82(t,3H)

[0165] Compound (V) (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(sulfamate) To a stirred solution of chlorosulfonyl isocyanate (4.07 g, 28.6 mmol) in acetonitrile (20 mL) was added formic acid (1.32 g, 28.7 mmol) dropwise at room temperature. The resulting mixture was stirred overnight at room temperature. To the above mixture were added (4aR,10aR)-1-propyl-2H,3H,4H,4aH,5H,10H,10aH-benzo[g]quinoline-6,7-diol (1.50 g, 5.7 mmol) and N,N-dimethylacetamide (10 mL). The resulting mixture was stirred at room temperature for an additional 6 hours. The reaction was quenched by adding ammonium hydroxide solution (10 mL) at room temperature. The resulting mixture was concentrated under reduced pressure. Preparative HPLC (column: XBridge Shield RP18 OBD column, 19 * The residue was purified by HPLC (250 mm, 10 μm; mobile phase A: water (10 mMol / L NH4HCO3), mobile phase B: ACN; flow rate: 25 mL / min; gradient: 17% B to 32% B in 10 min; 254 nm) to give (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(sulfamate).

[0166] Example 2 - In vivo conversion to the dopamine agonist (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol The examples of the present invention demonstrate that selected compounds of the present invention are converted to Compound (I) in vivo in rats.

[0167] PK study in rats For experiments involving compounds (Ia), (Ib), (Ic), (Id-iia), (Id-iib), and (Id-iiab), the compounds were synthesized as described in International Publication No. WO 2019101917, Liu et al., J. Med. Chem. (2006), 49:1494-1498, Liu et al., Bioorganic Med. Chem. (2008), and International Publication No. WO 2009 / 026934. Approximately 0.68 mL of blood sample was collected from the tail or sublingual vein and placed in a pre-chilled K3EDTA tube containing 80 μL of 100 mg / mL ascorbic acid in water and 40 μL of an inhibitor solution containing 0.5 M citric acid and 100 mM D-sugar acid 1,4 lactone. The tube was gently inverted 6-8 times to mix thoroughly and then placed on wet ice. The collection tube was placed on wet ice for up to 30 minutes before centrifugation (3000×G for 10 minutes at 4°C). After removal from the wet ice, centrifugation was initiated immediately. Immediately after centrifugation, the sample was returned to wet ice. Two subsamples of 130 μL of plasma were transferred to each of two appropriately labeled cryotubes containing pre-chilled formic acid (20% v / v in water). The tube caps were immediately replaced, and the plasma solution was thoroughly mixed by gently inverting 6-8 times. Plasma samples were placed on water ice whenever possible within 60 minutes of sampling and stored frozen at nominally -70°C.

[0168] For experiments involving compounds (II) and (III), the protocol described above was used, except that KEDTA tubes were prepared with 80 μL of 100 mg / mL ascorbic acid and 40 μL of a stabilizing aqueous solution containing 100 mg / mL citric acid, 21 mg / mL D-saccharic acid 1,4 lactone, and 29 mg / mL tris-(2-carboxyethyl)phosphine (TCEP).

[0169] Plasma samples were analyzed by UPLC-MS / MS following solid-phase extraction or direct protein precipitation. MS detection was performed using electrospray in positive ion mode by monitoring the specific mass / charge transition of compound (I) using an internal standard to correct the response. Concentration-time data were analyzed using standard software using appropriate non-compartmental techniques to obtain estimates of derived PK parameters.

[0170] Apparatus used for the analysis of compound (I) from administering compound (Ia): Mass spectrometer (LC-MS / MS): Waters Acquity-Sciex API 5000. Analytical column: Waters BEH UPLC Phenyl 100 x 2.1 mm column, 1.7 micrometer particle size. Mobile phase A: 20 mM ammonium formate (aqueous) + 0.5% formic acid. Mobile phase B: acetonitrile. Gradient: 95 / 5% to 2 / 98% in 6.1 minutes. Flow rate: 0.5 mL / min. MRM (multiple reaction monitoring) monitoring of test items and added analytical standards. Administration of Compound (Ia) and Blood Sampling: Han Wistar rats were provided by Charles River Laboratories, Sulzfeld, Germany. An automatically controlled artificial 12-hour light and dark cycle was maintained. The rats were fed a standard laboratory diet (Altromin 1324 pellets) obtained from Brogaarden. The rats had free access to food. During the study (a 4-week toxicity study), rats were orally administered a dose of (Ia) once daily by gavage. From rats administered 300 micrograms / kg of (Ia), blood samples from three male satellite animals were collected at the following time points on day 29: 0.5, 1, 2, 4, 6, 8, 12, and 24 hours after administration.

[0171] Equipment used for the analysis of compound (I) from the administration of compound (Ib): Mass spectrometer (LC-MS / MS): Waters Acquity-Sciex API5000. Analytical column: Waters BEH UPLC Phenyl 100 x 2.1 mm column, 1.7 micrometer particle size. Mobile phase A: 20 mM ammonium formate (aqueous) + 0.5% formic acid. Mobile phase B: acetonitrile. Gradient: 95 / 5% to 2 / 98 in 6.1 minutes. Flow rate: 0.5 mL / min. MRM monitoring of test items and added analytical standards. Administration of Compound (Ib) and Blood Sampling: Han Wistar rats were provided by Charles River Laboratories (UK). An automated artificial 12-hour light and dark cycle was maintained. Rats were fed a standard laboratory diet (Teklad 2014C Diet). Rats had free access to food. During the study (a 26-week toxicity study), rats were orally administered a dose of (Ib) once daily by gavage. Blood samples from three male satellite animals from rats administered 300 micrograms / kg of (Ib) were collected at the following time points on day 182: 0.5, 1, 2, 4, 8, and 24 hours post-dose.

[0172] Equipment used for the analysis of compound (I) from the administration of prior art compound (Ic) and (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl hydrogen sulfate (compound Id-iia) and (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-yl hydrogen sulfate (compound Id-iib), (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinoline-6,7-diylbis(hydrogen sulfate) (compound (Id-iiab)): Mass spectrometer (LC-MS / MS): Waters Acquity-Waters Xevo TQ-S. Analytical column: Acquity BEH C18 100 x 2.1 mm, 1.7 micrometers. Mobile phase A: 20 mM ammonium formate + 0.2% formic acid. Mobile phase B: acetonitrile + 0.2% formic acid. Gradient: 95 / 5% to 5 / 95% in 11.0 minutes. Flow rate: 0.3 mL / min. MRM monitoring of test items and added analytical standards.

[0173] Administration of compounds (Id-iia) and (Id-iib) and blood sampling: Han Wistar rats were provided by Charles River Laboratories, Sulzfeld, Germany. An automated artificial 12-hour light-dark cycle was maintained. Rats were fed a standard laboratory diet (Altromin 1324 pellets) obtained from Brogaarden. Rats had free access to food. Male Han Wistar rats were orally gavaged with a single dose of Id-iia and Id-iib, respectively. Rats were administered 392 μg / kg of Id-iia and Id-iib, and blood samples from three male animals were collected at the following time points: Day 1: 1, 2, 4, 6, 8, and 24 hours post-dose.

[0174] Administration of compounds (Ic) and (Id-iiab) and blood sampling: Han Wistar rats were supplied by Envigo, UK. An automated artificial 12-hour light-dark cycle was maintained. Rats were fed a standard laboratory diet, Teklad 2014C. Rats had free access to food. Male Han Wistar rats were orally gavaged with a single dose of Ic and Id-iiab, respectively. Rats were administered 703 μg / kg of Id-iiab and 494 μg / kg of Ic. Blood samples from three male animals were taken at the following time points: Day 1: 1, 2, 4, 6, 8, and 24 hours post-dose.

[0175] Administration of Compounds (II) and (III) and Blood Sampling: Han Wistar rats were supplied by Envigo, UK. An automated artificial 12-hour light / dark cycle was maintained. Rats were fed standard laboratory diet Teklad 2014C. Rats had free access to food. Male Han Wistar rats were given a single oral gavage dose of Compound (II) or (III). Rats were administered 390 μg / kg of Compound (II) and 390 μg / kg of Compound (III). Blood samples from three male animals were taken at the following time points: Day 1 post-dose: 5 minutes, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours.

[0176] Equipment used for the analysis of compound (I) from the administration of compounds (II) and (III): Mass spectrometer (LC-MS / MS): Waters Acquity-Waters Xevo TQ-S. Analytical column: Acquity BEH C18 100 x 2.1 mm, 1.7 μm. Mobile phase A: 20 mM ammonium formate + 0.2% formic acid. Mobile phase B: acetonitrile + 0.2% formic acid. Gradient: 95 / 5% to 5 / 95% in 9.1 minutes. Flow rate: 0.3 mL / min. MRM monitoring of test items and added analytical standards.

[0177] The measured mean plasma concentrations of (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (Compound (I)) in plasma at various time points after administration of Compounds (II) and (III) from three subjects per time point are shown in Figures 2 and 1, respectively.

[0178] Table 2 below further shows PK parameters based on the measured mean plasma concentrations.

[0179] The results in Table 2 show that the 24-hour plasma exposures for test compounds (II) and (III) are lower than those observed for prior art compounds (Ia) and (Ib), and higher than those observed for prior art compound (Ic), which was not found to be useful as a prodrug. Furthermore, the Cmax of compound (I) observed after administration of both compounds (II) and (III) is lower than the Cmax achievable from administration of prior art compounds (Ia) and (Ib) and prior art sulfate conjugate compounds (Id-iia) and (Id-iib).

[0180] Because the peak concentration (Cmax) of Compound (I) that would be expected to induce side effects is lower than that of Compounds (II) and (III), higher doses of the compounds of the invention may be administered to potentially achieve higher total plasma concentrations of Compound (I) compared to the concentrations achievable from administration of Compounds (Ia), (Ib), (Id-iia) and (Id-iib).

[0181] For compound (II), Tmax was observed after 1 hour, similar to prior art compounds (Ia), (Ib) and (Ic), while prior art compounds (Id-iia), (Id-iib) and (Id-iiab) had Tmax after several hours.

[0182] [Table 2]

[0183] Example 3 - Solubility of compounds of the present invention The following examples demonstrate that the compounds of the present invention have increased solubility at pH 6.0 compared to the prior art sulfate derivatives.

[0184] Testing Procedure: For compound (III), a sample was prepared with an excess of compound (III) to establish a saturated solution. 4.2 mg of compound (III) was transferred to a vial, and 0.5 mL of buffer (25 mM phosphate buffer, NaH2PO4 / Na2HPO4, pH 6) was added. The sample was mixed by rotation for 24 hours. The pH of the sample was measured at t = 0 (before rotation) and t = 24 h (24 hours after rotation). Subsequently, a portion of the sample was filtered through a 0.22 μm polyvinylidene fluoride filter, discarding the first few drops, and analyzed by reverse-phase HPLC (C) using an eluent of 20 mM ammonium chloride buffer (pH 2.4) in an 80:20 mixture of methanol and HCl. 18 The dissolved compound (III) content was quantified using a column chromatography (HPLC, 3.5 μm, 4.6 × 150 mm column).

[0185] The remaining undissolved material was extracted and air-dried on a metal plate for approximately 20 minutes before being analyzed by X-ray powder diffraction (XRPD). XRPD diffractograms were obtained on a PANalytical X'Pert PRO X-ray diffractometer using CuKa1 radiation (λ = 1.5406 A). Samples were measured in reflection mode using an X'Celerator detector over the 2θ range of 3 to 39.9°.

[0186] For compound (Id-iib), a similar analysis was performed using 0.799 mg of compound (Id-iib) in 0.5 mL of buffer.

[0187] Additionally, ADMET Predictor™ version 10.3.0.7, Simulations Plus, Inc. was used to predict values ​​of physical and chemical properties.

[0188] [Table 3]

[0189] result: The measured solubility of Compound III was determined to be 0.89 mg / mL. The crystalline forms before and after mixing with buffer were identical, indicating no solid form change.

[0190] For the prior art sulfate derivative compound (Id-iib), the solubility was determined to be 0.037 mg / mL. The crystalline form before and after mixing with buffer was identical, indicating no solid form change.

[0191] The sulfate derivative compounds (Id-iib) and (Id-iia) are structurally very similar, resulting in very similar predicted pKa values ​​and LogP and D. Therefore, the solubility of compound (Id-iia) is expected to be very similar to the measured solubility of compound (Id-iib).

[0192] Furthermore, the sulfamate derivatives compounds (II) and (III) are structurally very similar, resulting in very similar predicted pKa values ​​and LogP and D. Therefore, the solubility of compound II is expected to be very similar to the measured solubility of compound III.

[0193] In summary, the data of the present invention demonstrate that the compounds of the present invention have higher solubility than the prior art sulfate derivatives.

[0194] Example 4: Conversion of compounds of the invention in rat and human liver S9 Compounds (II), (III), (Id-iia), and (Id-iib) were incubated at 1 μM with rat and human liver S9 fractions suspended in 50 mM phosphate buffer, pH 7.4, containing 5 mM MgCl2, 200 U / mL superoxide dismutase, and 1 mM ascorbic acid. Human liver S9 (pooled from 50 donors) and rat liver S9 (pooled from 240 Wistar Han rats) fractions were purchased from Sekisui XenoTech, USA. The protein concentration in the incubation was 4 mg / mL. Incubations were performed at 37 °C in a 96-well plate with a total incubation volume of 150 μL / well using an automated Hamilton liquid handling system. Each compound was incubated in triplicate in three wells per time point. The liver S9 suspensions were preincubated at 37 °C, and the reaction was initiated by adding a stock solution of the test compound to the incubation wells. Test compounds were dissolved in dimethyl sulfoxide (DMSO) and further diluted in water before adding the stock solution to the incubation wells. The final DMSO concentration in the incubation was 0.1%. Test compounds were incubated with liver S9 fractions for 0, 5, 10, 15, 30, 45, and 60 minutes. Incubations were terminated by transferring 100 μL of the incubation sample to a 96-well plate containing 100 μL of cold (approximately +4°C) stop reagent containing 2% formic acid, 20 mg / mL ascorbic acid, 10 mg / mL citric acid, and 3 mg / mL TCEP (tris(2-carboxyethyl)phosphine). After mixing, the samples were transferred to Nunc 1.0 mL cryotubes and immediately frozen at -80°C until analysis. Compound (I) concentrations were determined by solid-phase extraction of the samples followed by LC-MS / MS analysis. The increase in the concentration of Compound (I) at different time points was calculated by subtracting the concentration of Compound (I) in the sample taken at time 0 from the concentration of Compound (I) in the sample taken at different time points.

[0195] Equipment used for the analysis of compound (I) from compounds (II), (III), (Id-iia) and (Id-iib): Mass spectrometer (LC-MS / MS) Waters Acquity-Waters Xevo TQ-S. Analytical column Acquity BEH C18 50 × 2.1 mm, 1.7 μm. Mobile phase A: 0.2% formic acid in 20 mM ammonium formate. Mobile phase B: 0.2% formic acid in acetonitrile. Gradient moving from 5% B to 95% B in 3.5 min. Flow rate 0.6 mL / min. Multiple reaction monitoring (MRM) with positive polarization was applied to monitor the precursor-product ion pair transition of compound (I) and its deuterated internal standard.

[0196] result: Figures 3 and 4 show that for both human liver S9 (Figure 3) and rat liver S9 (Figure 4), an increase in the concentration of compound (I) was measured at various time points after incubation of the S9 fraction with compounds (II), (III), (Id-iia), and (Id-iib). Data based on human S9 liver fractions (Figure 3) show that compounds (II) and (III) of the present invention have increased conversion to compound (I) in human liver S9 fractions compared to the prior art sulfate conjugates (compounds (Id-iia) and (Id-iib)). For rat liver S9 incubation, it can be seen that compounds (II), (III), and (Id-iib) are converted to compound (I).

[0197] References U.S. Patent No. 4,543,256 International Publication No. 2001 / 078713 Pamphlet International Publication No. 02 / 100377 Brochure International Publication No. 2009 / 026934 Brochure International Publication No. 2009 / 026935 Brochure International Publication No. 2010 / 097092 Brochure International Publication No. 2019101917 Brochure Alexander et Crutcher,(1990)Trends in Neuroscience 13:266-71; Bibbiani et al.,Chase Experimental Neurology(2005),192:73-78; Campbell et al.,Neuropharmacology(1982);21(10):953-961; Cannon et al.,J.Heterocyclic Chem.(1980);17:1633-1636; Cavero and Guillon,J.Pharmacol.Toxicol.Methods(2014),69:150-161; Delong,(1990)Trends in Neuroscience 13:281-5; Elger W,Schwarz S,Hedden A et al.:Sulfamates of various estrogens are prodrugs with increased systemic and reducedHepatic estrogenicity at oral application.J.Steroid.Biochem.Mol.Biol.(1995)55:395-403 Elger,W;Barth,A;Hedden,A;Reddersen,G;Ritter,P;Schneider,B;Zuechner,J;Krahl,E;Mueller,K;Oettel,M;Schwarz,S;“Estrogen sulfamates:a new approach to oral estrogen therapy”;Reproduction,fertility and development(2001)13(4)p.297-305 Gerfen et al,Science(1990)250:1429-32; Giardina and Williams;CNS Drug Reviews(2001),Vol.7(3):305-316; Grosset et al.,Acta Neurol Scand.(2013),128:166-171; Hauser et al.,Movement Disorders(2016),Vol.32(9):1367-1372; Liu et al.,J.Med.Chem.(2006),49:1494-1498; Liu et al.,Bioorganic Med.Chem.(2008),16:3438-3444; Poewe et al.,Nature Review,(2017)vol 3 article 17013:1-21; Sprenger and Poewe,CNS Drugs(2013),27:259-272; Sozio et al.,Exp.Opin.Drug Disc.(2012);7(5):385-406; Stahl and Wermuth(Eds)“Handbook of Pharmaceutical salts.Properties,selection,and use”,Wiley-VCH,2008 Stain-Texier et al.,Drug Metab.and Disposition(1998)26(5):383-387; Wiley-Interscience(publisher):Compendium of Organic Synthetic Methods,Vol.I-XII

Claims

1. The following formula (Id): 【Chemistry 1】 (In the formula, R1 and R2 each independently represent H or the following substituent (iii): 【Chemistry 2】 (In the formula, * indicates the point of attachment to the oxygen, R3 is selected from H and COR4; R4 is selected from H and C1-C6 alkyl. is selected from With the proviso that R1 and R2 cannot both be H. or a pharma- ceutically acceptable salt thereof.

2. 2. The compound of claim 1, wherein one of R1 or R2 is a substituent (iii) and the other is H, or a pharma- ceutically acceptable salt thereof.

3. The compound according to any one of claims 1 to 2, wherein both R1 and R2 are substituents (iii), or a pharma- ceutically acceptable salt thereof.

4. The compound according to any one of claims 1 to 3, wherein R3 is H, or a pharma- ceutically acceptable salt thereof.

5. The compound is (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate of the following formula (II) and (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate of the following formula (III): 【Chemistry 3】 The compound according to any one of claims 1 to 2, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of:

6. The compound is (4aR,10aR)-6-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-7-ylsulfamate represented by the following formula (II): 【Chemistry 4】 or a pharma- ceutically acceptable salt thereof. The compound according to any one of claims 1 to 2,

7. The compound is (4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-ylsulfamate represented by the following formula (III): 【Chemistry 5】 or a pharma- ceutically acceptable salt thereof. The compound according to any one of claims 1 to 2, which is:

8. 8. The compound according to any one of claims 1 to 7, or a pharma- ceutically acceptable salt thereof, in solid form.

9. A pharma- ceutically acceptable salt of the compound according to any one of claims 1 to 8.

10. A compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, for use as a medicament.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.

12. 12. The pharmaceutical composition of claim 11, which is an oral pharmaceutical composition comprising a tablet or capsule for oral administration.

13. 13. A pharmaceutical composition according to any one of claims 11 to 12 for use in the treatment of a neurodegenerative disease or disorder, including Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a neuropsychiatric disease or disorder, including schizophrenia, attention deficit hyperactivity disorder or drug addiction.

14. 14. A pharmaceutical composition according to claim 13 for use in the treatment of Parkinson's disease.

15. Use of the compound according to any one of claims 1 to 9 or a pharma- ceutical composition according to any one of claims 11 to 12 in the manufacture of a medicament for the treatment of a neurodegenerative disease or disorder, including Parkinson's disease, Huntington's disease, restless legs syndrome or Alzheimer's disease; or a psychiatric disease or disorder, including schizophrenia, attention deficit hyperactivity disorder or drug addiction.

16. 16. The use according to claim 15, wherein the medicament is for the treatment of Parkinson's disease.